<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783937</url>
  </required_header>
  <id_info>
    <org_study_id>OBGYN001</org_study_id>
    <nct_id>NCT02783937</nct_id>
  </id_info>
  <brief_title>Filgrastim for Premature Ovarian Insufficiency</brief_title>
  <acronym>FIL-POI</acronym>
  <official_title>Filgrastim for Treatment of Premature Ovarian Insufficiency: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Filgrastim is a Granulocyte-Colony Stimulating factor (G-CSF). It is an FDA approved drug.
      Very small embryonic-like stem cells (VSELs) are found in the ovary. Animal studies showed
      that these cells are able to regenerate the affected ovary. Studies on mice have shown that
      Filgrastim result in recovery of oogenesis after chemotherapy-induced gonadal failure (in
      2013, 2014, and 2015).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature ovarian insufficiency (POI) has no curative treatment until now. Filgrastim is an
      FDA approved Granulocyte-Colony Stimulating factor (G-CSF). Very small embryonic-like stem
      cells (VSELs) are found in the testis and ovary. VSELs are stem cells that have noticed to
      survive chemotherapy induced gonadal failure. Data from animal studies showed that
      stimulation of these stem cells result in generation of the affected gonads. Studies on mice
      have shown a promising stimulating effect of Filgrastim on recovery of spermatogenesis and
      oogenesis after chemotherapy-induced gonadal failure (in 2013, 2014, and 2015).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Return of menses</measure>
    <time_frame>6 months</time_frame>
    <description>Return of menses in patients with amenorrhea of at least 4 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>6 months</time_frame>
    <description>Occurrence of pregnancy as diagnosed by positive serum B-hCG and/or ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Estradiol</measure>
    <time_frame>6 months</time_frame>
    <description>Normalization of serum Estradiol as tested bi-weekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Anti-mullarian Hormone (AMH)</measure>
    <time_frame>6 months</time_frame>
    <description>Normalization of serum AMH in patients with AMH level less than 0.9 ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum FSH</measure>
    <time_frame>6 months</time_frame>
    <description>Normalization of serum FSH in patients with FSH level above 25 IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicular growth</measure>
    <time_frame>6 months</time_frame>
    <description>Growth of follicle to size at least 18 mm as monitored by transvaginal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>6 months</time_frame>
    <description>increase of endometrial thickness in women with thin endometrium (less then 8 mm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Filgrastim arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Injection of saline SC injection twice daily for five consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:
Phase A:
Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.
Phase B:
Injection of saline SC injection twice daily for five consecutive days.</description>
    <arm_group_label>Filgrastim arm</arm_group_label>
    <other_name>Granulocyte-Colony Stimulating Factor (G-CSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Injection of saline SC injection twice daily for five consecutive days</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with Premature Ovarian Insufficiency (POI): For the purpose of the research
             women is considered to have POI if she is aged less than 40 years and has amenorrhea
             of at least 4 month with FSH level above 25 IU/L (repeated twice &gt;4 weeks apart).

        Exclusion Criteria:

          -  Abnormal karyotype

          -  Previous pelvic or abdominal radiotherapy

          -  Previous surgical removal of the ovarian pathology

          -  Chronic disease: renal, liver, cardiac, malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad AM Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Egypt, Qena, South Valley University, faculty of Medicine</affiliation>
  </overall_official>
  <reference>
    <citation>Skaznik-Wikiel ME, McGuire MM, Sukhwani M, Donohue J, Chu T, Krivak TC, Rajkovic A, Orwig KE. Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy. Fertil Steril. 2013 Jun;99(7):2045-54.e3. doi: 10.1016/j.fertnstert.2013.01.135. Epub 2013 Feb 26.</citation>
    <PMID>23453120</PMID>
  </reference>
  <reference>
    <citation>Akdemir A, Zeybek B, Akman L, Ergenoglu AM, Yeniel AO, Erbas O, Yavasoglu A, Terek MC, Taskiran D. Granulocyte-colony stimulating factor decreases the extent of ovarian damage caused by cisplatin in an experimental rat model. J Gynecol Oncol. 2014 Oct;25(4):328-33. doi: 10.3802/jgo.2014.25.4.328. Epub 2014 Jun 18.</citation>
    <PMID>25142624</PMID>
  </reference>
  <reference>
    <citation>Benavides-Garcia R, Joachim R, Pina NA, Mutoji KN, Reilly MA, Hermann BP. Granulocyte colony-stimulating factor prevents loss of spermatogenesis after sterilizing busulfan chemotherapy. Fertil Steril. 2015 Jan;103(1):270-80.e8. doi: 10.1016/j.fertnstert.2014.09.023. Epub 2014 Nov 5.</citation>
    <PMID>25439845</PMID>
  </reference>
  <reference>
    <citation>Bhartiya D, Anand S, Parte S. VSELs may obviate cryobanking of gonadal tissue in cancer patients for fertility preservation. J Ovarian Res. 2015 Nov 17;8:75. doi: 10.1186/s13048-015-0199-2.</citation>
    <PMID>26576728</PMID>
  </reference>
  <reference>
    <citation>Roness H, Kalich-Philosoph L, Meirow D. Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents. Hum Reprod Update. 2014 Sep-Oct;20(5):759-74. doi: 10.1093/humupd/dmu019. Epub 2014 May 15. Review.</citation>
    <PMID>24833728</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Mohammad Abdel-Rahman Mohammad Ahmed</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Premature</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Failure</keyword>
  <keyword>Filgrastim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

